• Most Popular
  • Most Shared

Biogen moves long-acting Avonex to final trial-CEO

Wed Jan 7, 2009 4:27pm EST

Stocks

   

LOS ANGELES, Jan 7 (Reuters) - Biogen Idec Inc (BIIB.O) has moved a long-acting version of its multiple sclerosis drug, Avonex, into trials designed to meet requirements for regulatory approval, the company's chief executive said on Wednesday.

Stocks  |  Global Markets

CEO Jim Mullen said during an investor conference being held in New York that the company is studying dosing the drug once every two weeks as well as once monthly.

"I think we've got a good chance of similar efficacy as interferons," he said.

Patients in the trials will be treated for one year and full results will likely be available in two years, Mullen added. (Reporting by Deena Beasley; Editing by Andre Grenon)

Stocks
Global Markets


More from Reuters

Photo

Investors seen jumping the gun on airport security

BANGALORE (Reuters) - Investors' optimism surrounding the shares of airport security systems makers could be premature as interest in the companies' products after the Christmas Day plane scare is not expected to translate into immediate orders.

» More Top News
A hiring sign hangs in a window at PETCO in Falls Church, Virginia June 5, 2009.REUTERS/Kevin Lamarque

Dust off your resumes

Employers say they'll be adding headcount in the coming year. Here's where the jobs will be.  Full Article 

ECONOMY
Tiger Woods blows on his putter on the 10th hole during final round play of the Tournament Players Championship golf tournament at the TPC at Sawgrass in Ponte Vedra, Florida May 13, 2007.

Tiger's $12 billion scandal?

Shareholders of Tiger Woods' sponsors discover that along with the upside, there are big downside risks, too, a study shows.  Full Article 

Sports